Standard Biotools Inc.: Form 10-Q for the period ended Jun 30, 2019
Filed with the SEC on Aug 7, 2019 and accepted by EDGAR at Aug 7, 2019, 17:18 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2019-04-01 to 2019-06-30 | $28.2m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2019-01-01 to 2019-06-30 | $58.3m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2019-04-01 to 2019-06-30 | $12.8m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2019-01-01 to 2019-06-30 | $26.0m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2019-04-01 to 2019-06-30 | $15.4m | us-gaap:GrossProfit |
| Gross profit | 6 months2019-01-01 to 2019-06-30 | $32.4m | us-gaap:GrossProfit |
| Research and development | 3 months2019-04-01 to 2019-06-30 | $7.9m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2019-01-01 to 2019-06-30 | $16.2m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2019-04-01 to 2019-06-30 | $22.1m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2019-01-01 to 2019-06-30 | $45.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2019-04-01 to 2019-06-30 | −$14.6m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2019-01-01 to 2019-06-30 | −$28.8m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2019-04-01 to 2019-06-30 | $491.0k | us-gaap:InterestExpense |
| Interest expense | 6 months2019-01-01 to 2019-06-30 | $3.2m | us-gaap:InterestExpense |
| Income tax | 3 months2019-04-01 to 2019-06-30 | −$1.1m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2019-01-01 to 2019-06-30 | −$1.1m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2019-04-01 to 2019-06-30 | −$13.8m | us-gaap:NetIncomeLoss |
| Net income | 6 months2019-01-01 to 2019-06-30 | −$39.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2019-04-01 to 2019-06-30 | −$0.20 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months2019-01-01 to 2019-06-30 | −$0.61 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 6 months2019-01-01 to 2019-06-30 | −$25.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2019-01-01 to 2019-06-30 | $685.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2019-06-30 | $24.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-06-30 | $106.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2019-06-30 | $283.8m | us-gaap:Assets |
| Current liabilities | At period end2019-06-30 | $37.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2019-06-30 | $111.2m | us-gaap:Liabilities |
| Shareholders' equity | At period end2019-06-30 | $172.6m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001162194-19-000068. Last ingested by Listed: Nov 5, 2026, 21:16 ET. Listed shows no prices and gives no investment advice.